Ear acupressure plus dexamethasone to prevent nausea and vomiting from trastuzumab deruxtecan

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Trastuzumab deruxtecan commonly causes nausea and vomiting, particularly on the day of administration and during the following four days, and is considered high emetic risk. In this phase 2 interventional trial, participants receive auricular acupressure (bean seeds taped to specific points on one ear) plus an intravenous dose of dexamethasone within 30 minutes before trastuzumab deruxtecan. The study will track the incidence and severity of nausea and vomiting, appetite changes, gastrointestinal function (constipation, diarrhea, bloating), and safety over the early post-treatment period. The goal is to determine whether adding auricular point stimulation can reduce emesis or allow lower reliance on high-intensity antiemetic drug regimens.

Why it matters

Who can join: the full rules

Inclusion Criteria: Patients must meet the following inclusion criteria for the study:

* Age ≥ 18 years and ≤ 85 years;
* Breast cancer patients scheduled to undergo palliative treatment with trastuzumab deruxtecan;
* ECOG performance status score of 0-2;
* Normal hematological function (platelet count \> 80×10⁹/L; white blood cell count \> 3×10⁹/L; neutrophil count \> 1.5×10⁹/L);
* Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), and transaminase ≤ 5 times the ULN;
* No ascites, no gastrointestinal obstruction, normal coagulation function, and serum albumin ≥ 30g/L;
* Child-Pugh classification of liver function is Grade A;
* Serum creatinine \< ULN, or calculated creatinine clearance rate \> 50ml/min.

Exclusion Criteria: Patients who meet any of the following criteria will be excluded from the study:

* Local inflammation or infection of the auricle;
* Bleeding tendency or coagulation disorders;
* Severe ascites;
* Gastrointestinal obstruction;
* Hypertensive crisis or hypertensive encephalopathy;
* Severe uncontrolled systemic complications such as infection or diabetes mellitus;
* Clinically severe cardiovascular diseases, including cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), hypertension that is not well-controlled despite appropriate medication, unstable angina pectoris, congestive heart failure (NYHA Class 2-4), and cardiac arrhythmias requiring drug treatment;
* A history of or physical examination findings indicating central nervous system diseases (e.g., primary brain tumor, epilepsy uncontrolled by standard treatment, any history of brain metastasis or stroke);
* Hypersensitivity to any drugs used in the study;
* Pregnant or lactating women;
* Presence of any other diseases, functional impairment caused by metastatic lesions, or suspicious disorders identified during physical examination, which suggest contraindications to the study drugs or place the patient at high risk of treatment-related complications;
* Inability or unwillingness to comply with the study protocol.

Where it's running

• Second Affiliated Hospital of Zhejiang University School of Medicine
  Hangzhou, China Recruiting

Study contacts

• Study coordinator: Juan Wang
• Email: wangjuan.happy@hotmail.com
• Phone: 8617816190946

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Auricular point stimulation with dexamethasone versus standard antiemetics for nausea from trastuzumab deruxtecan

  This trial tests whether adding ear acupuncture-style stimulation to dexamethasone can prevent and reduce nausea and vomiting caused by trastuzumab deruxtecan in breast cancer patients, compared with the usual antiemetic regimen.

  Recruiting Phase 3 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07716189

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Trastuzumab Rezetecan and Gemcitabine before surgery for HER2-positive UTUC

  This study tests whether giving trastuzumab deruxtecan with gemcitabine before and around surgery can improve outcomes for people with HER2-positive upper tract urothelial cancer.

  Recruiting at 10 sites Phase 2 Tongji Hospital · Huanggang, Hubei and 9 other locations · NCT07741448

• Foslorapitant with Palonosetron to Help Prevent Nausea and Vomiting from Trastuzumab Rezetecan

  A single-arm study tests whether giving foslorapitant plus palonosetron can prevent chemotherapy-induced nausea and vomiting in adults receiving Trastuzumab Rezetecan.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07726433

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.